Zobrazeno 1 - 6
of 6
pro vyhledávání: '"B L, Storer"'
Autor:
R N, Willette, N, Aiyar, T L, Yue, M P, Mitchell, J, Disa, B L, Storer, D P, Naselsky, J M, Stadel, E H, Ohlstein, R R, Ruffolo
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 289(1)
Clinical studies conducted with carvedilol suggest that beta-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure. However, many beta-adrenoceptor antagonists are weak partial agonists and possess significant
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 271(1)
Angiotensin II (AII) has the potential to promote vascular smooth muscle (VSM) hypertrophy and hyperplasia; however, the mechanisms involved in AII stimulation of VSM growth are not fully understood. The AII receptor subtypes in VSM responsible for s
Autor:
Lynne M. Vickery-Clark, J D Elliott, Giora Z. Feuerstein, Stephen A. Douglas, Eliot H. Ohlstein, Calvert Louden, B L Storer, T Hart
Publikováno v:
Circulation research. 75(1)
The observation that levels of the mitogenic peptide endothelin-1 are elevated in the human coronary sinus after percutaneous transluminal coronary angioplasty (PTCA) has implicated endothelin-1 in the etiology of vascular restenosis. The present stu
Publikováno v:
Circulation research. 69(3)
Modulation of the biosynthesis of the vasoconstrictor peptide endothelin was studied in cultured endothelial cells. Immunoreactive endothelin (irET) levels were significantly elevated in conditioned medium from bovine pulmonary artery endothelial (BP
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 246(2)
The purpose of this investigation was to examine the potential beneficial effect of the selective endoperoxide/thromboxane A2 (TxA2) receptor antagonist, sulotroban (BM 13.177), on tissue type plasminogen activator (tPA)-induced coronary thrombolysis
Publikováno v:
Thrombosis and haemostasis. 61(2)
This study compared the anti-platelet effect of Ac-RGDS-NH2 which is a peptide fragment from fibrinogen to Ac-RGES-NH2 in which the aspartic acid (D) of Ac-RGDS-NH2 has been replaced by glutamic acid (E). When Ac-RGDS-NH2 was infused intracoronary at